Details for Patent: 9,561,251

Which drugs does patent 9,561,251 protect, and when does it expire?

Patent 9,561,251 protects VELPHORO and is included in one NDA.

Protection for VELPHORO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has ninety-two patent family members in thirty-four countries.

Summary for Patent: 9,561,251

Patent landscape, scope, and claims:

Title:	Pharmaceutical compositions
Abstract:	Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
Inventor(s):	Weibel; Ludwig Daniel (Waldstatt, CH), Philipp; Erik (Wittenbach, CH)
Assignee:	Vifor Fresenius Medical Care Renal Pharma Ltd. (St. Gallen, CH)
Application Number:	12/743,120
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,561,251
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Compound; Process; Dosage form;

Drugs Protected by US Patent 9,561,251

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vifor Fresenius	VELPHORO	ferric oxyhydroxide	TABLET, CHEWABLE;ORAL	205109-001	Nov 27, 2013		RX	Yes	Yes					Y

Foreign Priority and PCT Information for Patent: 9,561,251

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	07120837	Nov 16, 2007

PCT Information
PCT Filed	November 13, 2008	PCT Application Number:	PCT/EP2008/065444
PCT Publication Date:	May 22, 2009	PCT Publication Number:	WO2009/062993

International Family Members for US Patent 9,561,251

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	069312
Australia	2008322963
Brazil	PI0820308
Canada	2700444
China	101861146
China	104688702
China	106619710